<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03340376</url>
  </required_header>
  <id_info>
    <org_study_id>BGOG-cx3</org_study_id>
    <nct_id>NCT03340376</nct_id>
  </id_info>
  <brief_title>Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer</brief_title>
  <official_title>Prospective Randomized Phase II Trial Comparing Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, randomized phase II trial to evaluate the safety and
      efficacy of atezolizumab in patients with recurrent cervical cancer in second line therapy. A
      total of 48 patients will be randomized in 3 arms, each arm consisting of 16 patients:

      Arm A: atezolizumab monotherapy q3w Arm B: atezolizumab combined with doxorubicin q3w Arm C:
      doxorubicin monotherapy q3w
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2017</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>after 9 months</time_frame>
    <description>after 9 months in the different arms by RECIST v1.1-criteria (doxorubicin, Atezolizumab and the combination of both)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>after 24 months</time_frame>
    <description>Overall survival in the different arms (doxorubicin, Atezolizumab and the combination of both)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>atezolizumab monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A fixed dose of 1200 mg atezolizumab will be administered intravenously on Day 1 of each 21-day cycle until progressive disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>atezolizumab combined with doxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A fixed dose of 1200 mg atezolizumab will be administered intravenously on Day 1 of each 21-day cycle. Doxorubicin will be administered on Day 1 of each 21-day cycle at a dose of 75mg/m² for a total of 6 cycles or until progressive disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>doxorubicin monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doxorubicin will be administered on Day 1 of each 21-day cycle at a dose of 75mg/m² for a total of 6 cycles or until progressive disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>atezolizumab</description>
    <arm_group_label>atezolizumab monotherapy</arm_group_label>
    <arm_group_label>atezolizumab combined with doxorubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin</description>
    <arm_group_label>atezolizumab combined with doxorubicin</arm_group_label>
    <arm_group_label>doxorubicin monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Squamous cell or adenocarcinoma of the cervix

          -  At least one prior chemotherapy regimen for recurrent or advanced disease with a
             platinum-taxane combination, but not more than two lines of chemotherapy or targeted
             therapy in recurrent/advanced setting

          -  Measurable disease

          -  ECOG≤2

          -  Adequate pretreatment hematologic, renal and hepatic function test

          -  Patients are allowed to have had bevacizumab during their prior treatment

          -  Evidence of non-childbearing status for women of childbearing potential

        Exclusion Criteria:

          -  History of invasive malignancy other than cervical cancer unless there is no
             recurrence of these other primary tumors the last 3 years.

          -  Previous anthracycline-based chemotherapy

          -  Central nerve system metastases and leptomeningeal disease

          -  Active or history of autoimmune disease

          -  Prior allogenic bone marrow transplantation or prior solid organ transplantation

          -  History of idiopathic pulmonary fibrosis

          -  Known positive test for HIV, or active hepatitis B or hepatitis C

          -  Known active tuberculosis

          -  Severe infection within 4 weeks prior to initiation of study treatment

          -  Prior immunotherapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ignace Vergote, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joke De Roover, PhD</last_name>
    <phone>+3216347419</phone>
    <email>bgog@engot.eu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZLeuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joke De Roover</last_name>
      <phone>+3216347419</phone>
      <email>joke.deroover@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Ignace Vergote</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rawand Salihi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

